NEKTAR THERAPEUTICS — Form 4
Filed July 2, 2026 · analyzed by the Insider Agent
4
▼ Likely negative
significance 49/100
What the filing says
Chief R&D Officer Zalevsky Jonathan (NKTR) sold 6K shares (~$398K) on the open market (37% of holdings). Large sale — ~37% of holdings.
Why this rating
Large sale — ~37% of holdings.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.